Foreign brokerages remain cautious on the road ahead for the Indian equity markets. Though analysts at Nomura have revised their March 2026 Nifty target to 26,140 levels from the earlier 24,970,......
The correction seen in the stock markets thus far is insufficient and there are significant downside risks, given the way macroeconomic data is shaping up, a Nomura equity strategist said on......
Indian equity markets have a limited upside potential in the near-term as they negotiate the ensuing cyclical slowdown, wrote analysts at Nomura in a recent coauthored report led by Saion......
The company has launched only 3 new products during 2015 when compared to 14 launches in 2014 Dr Reddy’s Laboratories (DRL) is likely to leverage its relationship with existing and new......
Thus far in FY21, BSE, NSE have rallied 70 per cent and 71 per cent, respectively. Foreign portfolio investors (FPIs) continue to bet big on ‘India story’ with their net investment in......